Home / Going-concern warnings / Akari Therapeutics Plc
Filed 2025-08-13 路 Form 10-Q 路 Accession 0001641172-25-023569 nano
Price before filing: $40.8 (2025-08-12 close, split/dividend-adjusted)
Market cap at flag: $641,808 (2025-08-13) 路 Latest: $14.7M (2026-10-16)
| Window | AKTX | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -22.6% | +2.3% | -24.9% | 2025-09-12 |
| 90 days | -42.0% | +6.6% | -48.6% | 2025-11-11 |
| 180 days | -75.7% | +8.6% | -84.3% | 2026-02-09 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"These factors raise substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-06-30)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.